{
    "2020-10-14": [
        [
            {
                "time": "",
                "original_text": "医疗ETF年内大涨80%居股票型ETF第一",
                "features": {
                    "keywords": [
                        "医疗",
                        "ETF",
                        "大涨",
                        "80%",
                        "股票型"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "IVD行业事件点评：三季度新冠业务预期差显着 建议把握投资窗口期",
                "features": {
                    "keywords": [
                        "IVD",
                        "行业",
                        "事件",
                        "点评",
                        "三季度",
                        "新冠",
                        "业务",
                        "预期差",
                        "投资窗口期"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2020年四季度投资策略：业绩验证化解估值压力",
                "features": {
                    "keywords": [
                        "医药",
                        "行业",
                        "2020",
                        "四季度",
                        "投资策略",
                        "业绩验证",
                        "估值压力"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020三季度业绩前瞻：板块分化明显 医疗服务等板块有序复苏",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业",
                        "2020",
                        "三季度",
                        "业绩前瞻",
                        "板块分化",
                        "医疗服务",
                        "复苏"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技",
                        "医疗服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}